ArticleGastroenterology and hepatology from bed to bench2025
Introducing ICAM1 as a possible drug target in treatment of eosinophilic esophagitis.
Article in Gastroenterology and hepatology from bed to bench, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Determining of more details of Eosinophilic esophagitis (EoE) molecular mechanism is the main aim of this study. Background: EoE is a chronic inflammatory disease associated with eosinophilic infiltration of the squamous epithelium and malfunction of immune system. Roles of number interleukins such as IL4, IL5, and IL13 are highlighted as the dysregulated genes innEoE. Methods: The significant differentially expressed genes (DEGs) of patient sample versus health controls are explored from Gene Expression Omnibus database and evaluated via GEO2R and directed protein-protein interaction (PPI) analyses to find the key genes that promote EoE. Gene ontology enrichment was applied to screen the critical genes. Results: IL1B, ICAM1, MAPK3, RAC2, IFNG, HGF, FGF2, IRS1, CCL2, GRAP, GNAO1, TBX21, IGF1, SPI1, BMP4, FLT4, MMP2, and PDGFRB were pointed out as the critical genes associated with EoE disease. Significant roles of IL1B and FGF2 were considered as important molecular event in EoE promotion. ICAM1 was highlighted as a possible drug target in EoE treatment. Conclusion: in conclusion, ICAM1 is an excellent actor in EoE disease which have controlled by the top actors as IL1B and FGF2. However, it has controlled by IFNG. Regulation of ICAM1 is suggested as a possible therapeutic protocol to control EoE progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.